The OSLER-1 trial was an open-label, randomized,
controlled study conducted at 190 centers
that participated in at least one of five phase 2
studies of evolocumab.14-19 Analogously, the OSLER-2
trial was an open-label, randomized, controlled
study conducted at 305 centers that participated
in at least one of seven phase 3 studies
of evolocumab